Abstract

Alzheimer disease (AD) is the most prevalent form of dementia although the underlying cause(s) remains unknown at this time. However, neuroinflammation is believed to play an important role and suspected contributing immune parameters can be revealed in studies comparing patients at the stage of amnestic mild cognitive impairment (aMCI) to healthy age-matched individuals. A network of immune regulatory cells including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) maintains immune homeostasis but there are very few data on the role of these cells in AD. Here, we investigated the presence of these cells in the blood of subjects with aMCI and mild AD (mAD) in comparison with healthy age-matched controls. We also quantitated several pro- and anti-inflammatory cytokines in sera which can influence the development and activation of these cells. We found significantly higher levels of MDSCs and Tregs in aMCI but not in mAD patients, as well as higher serum IL-1β levels. Stratifying the subjects based on CMV serostatus that is known to influence multiple immune parameters showed an absence of differences between aMCI subjects compared to mAD patients and healthy controls. We suggest that the increase in MDSCs and Tregs number in aMCI subjects may have a beneficial role in modulating inflammatory processes. However, this protective mechanism may have failed in mAD patients, allowing progression of the disease. This working hypothesis obviously requires testing in future studies.

Highlights

  • Alzheimer disease (AD) is the most frequent neurodegenerative disease for which aging is the most important risk factor [1, 2]

  • As a follow-up, we were interested to determine the phenotype of the common myeloid-derived suppressor cells (MDSCs) lineages and, those derived from neutrophils since there is no data in the literature concerning the number of these cells in amnestic mild cognitive impairment (aMCI) or mild AD (mAD)

  • Results showed a significant increase of MDSCs in the peripheral blood of aMCI subjects in contrast to healthy controls and mAD patients (Figure 1)

Read more

Summary

Introduction

Alzheimer disease (AD) is the most frequent neurodegenerative disease for which aging is the most important risk factor [1, 2]. AD is a chronic inflammatory disease that mainly involves the brain in its clinical manifestations, it is a systemic disease [5]. The preclinical stages of AD may last for decades before overt manifestations of the first symptoms are recognized. This is the case of amnestic mild cognitive impairment (aMCI) that is termed mild neurocognitive disorder according to The Diagnostic and Statistical Manual of Mental Disorders (DSM 5) [6, 7]. The progression to full-blown AD is relatively slow, occurring over a number of years [8]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.